LifeStance Health Group (NASDAQ:LFST) CTO Vukasin Paunovich Sells 44,394 Shares of Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) CTO Vukasin Paunovich sold 44,394 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the sale, the chief technology officer owned 247,446 shares of the company’s stock, valued at $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

LifeStance Health Group Stock Up 6.3%

Shares of NASDAQ:LFST traded up $0.73 during trading on Wednesday, hitting $12.23. 6,069,393 shares of the company’s stock traded hands, compared to its average volume of 3,436,752. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average price of $10.10 and a 200-day moving average price of $8.12. LifeStance Health Group, Inc. has a 52 week low of $4.77 and a 52 week high of $12.43. The company has a market cap of $4.74 billion, a price-to-earnings ratio of 94.08 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.LifeStance Health Group’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.01) EPS. As a group, research analysts forecast that LifeStance Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst upgrades support the rally: BTIG Research raised its price target from $15 to $16 while maintaining a Buy rating. Morgan Stanley also reaffirmed its Buy rating, reinforcing Wall Street confidence in LifeStance’s growth prospects. BTIG Raises LifeStance Price Target Morgan Stanley Reaffirms Buy Rating
• Positive Sentiment: Zacks upgraded LFST to Rank #2 (Buy): The upgrade reflects growing optimism about LifeStance’s earnings prospects and could attract additional near-term buying interest. LifeStance Health Upgraded to Buy
• Positive Sentiment: Shares reached a new 52-week high after the analyst upgrade. The move reflects strong recent momentum, supported by LifeStance’s latest quarterly performance, which included revenue growth of 26.1% year over year and earnings above analyst expectations. LifeStance Sets New 52-Week High
• Neutral Sentiment: LifeStance released survey results highlighting demand for integrated mental-health services during perimenopause and menopause. The findings support the company’s brand and potential service demand but do not represent a direct financial forecast or new contract. LifeStance Menopause Mental Health Survey
• Negative Sentiment: COO Lisa K. Miller sold 47,912 shares worth approximately $520,000, reducing her ownership by 14.55%. While insider sales can be motivated by personal financial planning, the transaction may create a modest sentiment headwind after the stock’s strong advance. SEC Insider Trading Filing

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Canaccord Genuity Group boosted their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Barclays lifted their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group initiated coverage on LifeStance Health Group in a report on Friday, June 5th. They issued a “neutral” rating and a $9.00 price target on the stock. Finally, KeyCorp increased their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $11.62.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of LifeStance Health Group in the 2nd quarter valued at about $389,293,000. Vanguard Group Inc. raised its holdings in LifeStance Health Group by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after acquiring an additional 3,086,506 shares in the last quarter. Silversmith Partners I GP LLC acquired a new position in LifeStance Health Group during the fourth quarter valued at approximately $100,842,000. Dimensional Fund Advisors LP boosted its position in LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,461,215 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in LifeStance Health Group by 38.5% during the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after purchasing an additional 2,843,388 shares during the last quarter. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.